Commack: 
Non-Proliferative Diabetic Retinopathy Study.
New Treatment for Nonproliferative Diabetic Retinopathy
This is a multicenter, phase 2 study using a new drug named AKB9778 which inhibits VE-PTP and enhances Tie2. This has the potential to improve diabetic retinopathy. It is unique in that it does not require eye injections or lasers.It may help with other systemic diabetic issues.
HAWK Study
About this Study
The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
CEDAR Study
About this Study
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.
New Treatment for Neovascular Age-Related Macular Degeneration
Enrollment is Open
About this Study
This is a phase 3 study using Combercept which is a long- acting antiVEGF agent.
It is hoped that with this drug, patients will require fewer eye injections.
Genentech Yosemite Study
New Treatment for Diabetic Macular Edema
Now enrolling
About this Study
This is a phase 3 study looking at a new drug RO6867461. It has the potential to improve vision with fewer eye injections.
Graybug Vision
New Treatment for Neovascular Age-related Macular Degeneration
Enrolling Soon!
About this Study
This is a phase 2 study looking at a long release anti-VEGF which may require injections as infrequently as every 6 months.
